- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07708402
Healing Stigma Through Stories
Healing Stigma Through Stories: Learning From International Practices to Develop and Evaluate a Narrative Program for Individuals With Schizophrenia
This study is the first phase of the research project. The purpose of this phase is to develop and refine a narrative-based intervention designed to reduce self-stigma among people with schizophrenia.
A small pilot study will be conducted with 24 participants recruited from halfway houses in northern Taiwan. Eligible participants will receive the intervention, which consists of four group sessions and four individual sessions, held once a week for a total of eight weeks. The program uses narrative therapy techniques to help participants explore their personal experiences and reduce self-stigma. Participants will complete a workbook during the program, and the written content will be analyzed to better understand their experiences with stigma. Any personal information will be removed to protect participants' privacy. Before and after the intervention, participants will complete questionnaires on self-stigma, depression, social functioning, well-being, hope, and recovery. Information on medication use will also be collected. Group and individual sessions will be audio-recorded for research purposes. The questionnaire data and recordings will be used to evaluate the feasibility and preliminary effects of the intervention.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Li-Ting Huang, phD
- Phone Number: +8862-28267284
- Email: lthuang@nycu.edu.tw
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 years or older.
- Diagnosed with schizophrenia or schizoaffective disorder.
- Clinically stable at the time of study enrollment.
- Able to communicate in Mandarin Chinese or Taiwanese.
- Able to read and write and complete study questionnaires.
Exclusion Criteria:
- Individuals who lack the capacity to provide informed consent. Decision-making capacity will be assessed using a 10-item true/false questionnaire adapted from Okoli et al. (2018). Participants who answer fewer than 7 questions correctly will be excluded. Those who answer 7 or more questions correctly will receive an additional explanation from the research team. Only individuals who demonstrate a complete understanding of the study after this explanation will be enrolled.
- Unwilling to have the intervention sessions audio-recorded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healing Stigma through Stories
|
Four group sessions and four individual sessions, held once a week for a total of eight weeks.
The program uses narrative therapy techniques to help participants explore their personal experiences and reduce self-stigma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Internalized Stigma of Mental Illness Scale
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Beck Depression Inventory-II
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
|
Self-Reported Graphic version of the Personal and Social Performance Scale
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
|
Subjective Happiness Scale
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
|
Herth Hope Index
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
|
The questionnaire about the process of recovery
Time Frame: At baseline(T0) and through study completion, an average of 8 weeks
|
At baseline(T0) and through study completion, an average of 8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NYCU115040AF
- 115-2314-B-A49 -082 - (Other Grant/Funding Number: National Science and Technology Council)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia / Schizoaffective Disorder
-
Teva Branded Pharmaceutical Products R&D LLCCompletedSchizophrenia, Schizoaffective DisorderUnited States
-
Hoffmann-La RocheTerminatedSchizophrenia, Schizoaffective DisorderUnited States, Spain, Japan, Ukraine
-
Central Institute of Mental Health, MannheimCompletedSchizophrenia, Schizoaffective DisorderGermany
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia and Schizoaffective DisorderHungary, United States, Argentina, Canada, Czech Republic, Estonia, France, Latvia, Lithuania
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
AmgenCompletedSchizophrenia or Schizoaffective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka America PharmaceuticalCompletedSchizophrenia and Schizoaffective Disorder
-
University of Sao PauloUnknownSchizophrenia or Schizoaffective DisorderBrazil
-
Hoffmann-La RocheCompletedSchizophrenia, Schizoaffective DisorderUnited States, Japan, Ukraine, Russian Federation
-
Shu-Mei WangNot yet recruiting
Clinical Trials on Healing Stigma through Stories
-
University of Wisconsin, MadisonCompletedMental HealthUnited States
-
IRCCS Fondazione Stella MarisUniversity of Florence; IRCCS Eugenio Medea; Fondazione MondinoRecruiting